Abstract
A predisposition to developing immune thrombocytopenia (ITP) has not been reported in survivors of childhood cancer. We report a case series of childhood cancer survivors who developed an isolated thrombocytopenia in the presence of a normocellular bone marrow. Five children, two with endodermal sinus tumors and three with acute lymphoblastic leukemia, developed ITP at a median of 4 years (range: 0.2-8 years) after completion of therapy. We suggest the association of ITP in survivors of childhood malignancy may not be co-incidental as chemotherapy may cause persistent immune dysfunction.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Asparaginase / administration & dosage
-
Asparaginase / adverse effects
-
Bone Marrow Cells / pathology
-
Carmustine / administration & dosage
-
Carmustine / adverse effects
-
Child, Preschool
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Daunorubicin / administration & dosage
-
Daunorubicin / adverse effects
-
Etoposide / administration & dosage
-
Etoposide / adverse effects
-
Female
-
Humans
-
Infant
-
Male
-
Neoplasms / complications*
-
Neoplasms / drug therapy
-
Neoplasms / pathology
-
Platelet Count
-
Prednisone / administration & dosage
-
Prednisone / adverse effects
-
Purpura, Thrombocytopenic, Idiopathic / blood
-
Purpura, Thrombocytopenic, Idiopathic / etiology*
-
Purpura, Thrombocytopenic, Idiopathic / pathology
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
Substances
-
Vincristine
-
Etoposide
-
Cyclophosphamide
-
Asparaginase
-
Carmustine
-
Prednisone
-
Daunorubicin
Supplementary concepts
-
CBV protocol
-
PVDA protocol